Scholarlink

<p><i>NOTCH1</i> and <i>SF3B1</i> mutations are common in CLL, but their prognostic value for overall survival (OS) and progression-free survival (PFS), as well as time to first treatment (TTFT) and treatment-free survival (TFS), remains uncertain. This meta‐analysis systematically evaluates their impact.&#xa0;A systematic search of PubMed, Embase, Cochrane Library, and Web of Science was performed up to March 2025. Relevant study data and prognostic outcomes were extracted, and pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using fixed- or random-effects models based on heterogeneity. A total of 38 studies with 24,060 CLL patients met the criteria. Among them, 32 and 23 studies evaluated the prognostic impact of <i>NOTCH1</i> and <i>SF3B1</i> mutations, respectively. Compared to wild-type, <i>NOTCH1</i> mutations were associated with worse OS (HR = 1.88), PFS (HR = 1.42), TTFT (HR = 1.63), and TFS (HR = 2.46). <i>SF3B1</i> mutations similarly predicted poor OS (HR = 1.68), with HRs of 1.63, 1.24, and 1.70 for PFS, TTFT, and TFS. Subgroup analysis showed worse OS in older and treatment-naïve patients.&#xa0;These findings suggest that <i>NOTCH1</i> and <i>SF3B1</i> mutations are significant adverse prognostic markers in CLL. Increasing evidence supports their inclusion in clinical risk stratification and personalized treatment planning, especially when combined with patient-specific clinical and molecular features.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostic significance of in patients with chronic lymphocytic leukemia: A meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月30日

查看全文
  • Liping Huang,
  • Xinyi Shi,
  • Ningning Tang,
  • Juan Liu,
  • Yanli Liang,
  • Xin Wang

摘要

NOTCH1 and SF3B1 mutations are common in CLL, but their prognostic value for overall survival (OS) and progression-free survival (PFS), as well as time to first treatment (TTFT) and treatment-free survival (TFS), remains uncertain. This meta‐analysis systematically evaluates their impact. A systematic search of PubMed, Embase, Cochrane Library, and Web of Science was performed up to March 2025. Relevant study data and prognostic outcomes were extracted, and pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using fixed- or random-effects models based on heterogeneity. A total of 38 studies with 24,060 CLL patients met the criteria. Among them, 32 and 23 studies evaluated the prognostic impact of NOTCH1 and SF3B1 mutations, respectively. Compared to wild-type, NOTCH1 mutations were associated with worse OS (HR = 1.88), PFS (HR = 1.42), TTFT (HR = 1.63), and TFS (HR = 2.46). SF3B1 mutations similarly predicted poor OS (HR = 1.68), with HRs of 1.63, 1.24, and 1.70 for PFS, TTFT, and TFS. Subgroup analysis showed worse OS in older and treatment-naïve patients. These findings suggest that NOTCH1 and SF3B1 mutations are significant adverse prognostic markers in CLL. Increasing evidence supports their inclusion in clinical risk stratification and personalized treatment planning, especially when combined with patient-specific clinical and molecular features.